This inventor holds 2 USPTO granted patents. Top assignees: Fuso Pharmaceutical Industries, Ltd., Hokkaido University. Active years: 2020-2023.
Company Filing History:
2 out of 108 
2 out of 442 
Years Active: 2020-2023
Title: Satoshi Takagi: Innovator in Antibody Development
Introduction
Satoshi Takagi is a prominent inventor based in Hokkaido, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer detection. With a total of 2 patents, his work has the potential to impact cancer diagnostics and treatment.
Latest Patents
Takagi's latest patents focus on an anti-PD-L1 antibody designed for detecting PD-L1 in tumor cells, such as melanoma cells. The invention includes a light chain with specific amino acid sequences in its complementarity-determining regions (CDRs) and a heavy chain with its own unique sequences. This antibody composition serves as an active ingredient for detecting PD-L1, and the patent also outlines a method for preparing the antibody.
Career Highlights
Throughout his career, Satoshi Takagi has worked with notable institutions, including Hokkaido University and Fuso Pharmaceutical Industries, Ltd. His experience in these organizations has allowed him to collaborate with other experts in the field and advance his research.
Collaborations
Some of Takagi's coworkers include Yumiko Kagawa and Asami Nishimori. Their collaborative efforts have contributed to the success of his research and innovations.
Conclusion
Satoshi Takagi's work in developing anti-PD-L1 antibodies showcases his dedication to advancing cancer detection technologies. His contributions are vital in the ongoing fight against cancer, and his patents reflect his innovative spirit.